Targeting FASN in Breast Cancer and the Discovery of Promising Inhibitors from Natural Products Derived from Traditional Chinese Medicine by Wang, Z et al.
Title
Targeting FASN in Breast Cancer and the Discovery of
Promising Inhibitors from Natural Products Derived from
Traditional Chinese Medicine
Author(s) Cheng, C; Wang, Z; Chen, J
Citation Evidence-Based Complementary and Alternative Medicine, 2014,v. 2014, p. article no. 232946
Issued Date 2014
URL http://hdl.handle.net/10722/196315
Rights Creative Commons: Attribution 3.0 Hong Kong License
Review Article
Targeting FASN in Breast Cancer and the Discovery of
Promising Inhibitors from Natural Products Derived from
Traditional Chinese Medicine
Chien-shan Cheng, Zhiyu Wang, and Jianping Chen
School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong
Correspondence should be addressed to Jianping Chen; jpjpchen@yahoo.com
Received 17 September 2013; Revised 27 December 2013; Accepted 15 January 2014; Published 13 March 2014
Academic Editor: Min Li
Copyright © 2014 Chien-shan Cheng et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Molecular targeted therapy has been developed for cancer chemoprevention and treatment. Cancer cells process a fundamental
change in its bioenergetic metabolism from normal cells on an altered lipid metabolism, also known as the de novo fatty acid
synthesis, for sustaining their high proliferation rates. Fatty acid synthesis is now associated with clinically aggressive tumor
behavior and tumor cell growth and has become a novel target pathway for chemotherapy development. Although the underlying
mechanisms of the altered de novo fatty acid synthesis still remains unclear, recent progress has shown that by targeting Fatty
acid synthase (FASN), a key enzyme that catalyzes the synthesis of endogenous long chain fatty acid could be a critical target
for drug discovery. However, relatively few FASN inhibitors have been discovered. With the long history of clinical practices and
numerous histological case study reports, traditional Chinese medicine enjoys an important role in seeking bioactive anticancer
natural compounds. Herein, we will give an overall picture of the current progress of molecular targeted therapy in cancer fatty acid
synthesis, describe the advances in the research on natural products-derived FASN inhibitors and their potential for enhancing our
understanding of fatty acids in tumor biology, and may provide new therapeutic moieties for breast cancer patient care.
1. Introduction
1.1. Epidemiology of Breast Cancer. Breast cancer is the most
prevalent cancer and the second leading cause of mortality
in women worldwide [1]. According to the World Cancer
Report [2], breast cancer comprises 22.9% of all cancers in
women with an estimated 1.4 million new cases annually,
resulting in more than 458,000 deaths in 2008 [2]. It was
estimated that more than 1.6 million new cases of breast
cancer emerged worldwide in 2010 [1, 3]. Since most breast
cancers primarily affect women aged 50 and older, there is
a clear relationship between menopause and breast cancer
incidence [3–5]. During and after the onset of menopause,
changes in hormonal status and in other metabolic processes
contribute to the formation of a favorable microenviron-
ment for the development of breast cancer [5, 6]. Several
breast cancer treatment options have been considered to
be conventional strategies in the last century, namely, mas-
tectomy, chemotherapy, and radiotherapy, or a combination
of the three [3]. With the rapid development of molecular
medicines, novel therapeutic approaches, such as hormonal
therapy and molecular targeted therapy, have been proposed
to improve clinical outcome; however, the outcome of such
approaches is still not ideal [3, 5, 7].
1.2. Role of TCM in Drug Development. Over the past few
years, the development of complementary and alternative
medicine (CAM)has drawn great attention in cancer research
[8–12]. According to Newman and Cragg (2012), of the 175
small molecules approved worldwide as antitumor drugs
during the period from 1981 to 2010, among the 74.8%
nonsynthetic drugs, 85, or 48.6%, of them are either natural
products or directly derived from natural products [13].
During the period from 2002 to 2010, of the 110 new
drugs approved for cancer treatment, 37 of them originated
from natural products [13]. TCM has thousands of years of
experimentation on human beings. It has recently proved
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to be an important source for herb selection for drug
discovery. In addition, TCM formulas provide promising
sources for a more effective and less toxic treatment option
for cancer [8, 10, 14–16]. The increasing interest and progress
in seeking natural products has not only provided a chemical
understanding of herbal drugs and their antitumor function
but also contributed to the chemical bank for drug discovery
[8, 13].
1.3. Obesity and Breast Cancer. In recent years, there has been
increasing interest in the relationship between obesity and
cancer. Obesity has been identified as the second leading
cancer risk factor, after tobacco, especially for breast cancer
[17, 18]. Statistics on breast cancer incidence and body fat
indicate that those who reside in certain geographical areas,
characterized by consumption of a more energy-dense diet,
are at higher risk for breast cancer occurrence [1, 3, 19].
In addition, there is also a relation between body size and
breast cancer risk. Women with a BMI of 30 versus 20.0–
24.9 kg/m2 have an 82% increased risk for advanced cancer
and a 22% increased risk for localized cancer [4, 19–21]. De
novo lipogenesis, also known as de novo fatty acid synthesis,
is the metabolic pathway synthesizing fatty acids, one of the
essential substances for mammals, from nonlipid precursors,
which is then incorporated with dietary and adipose tissue-
derived fatty acid to produce triglyceride for energy storage
that occurs in both liver and adipose tissue [22–24]. Adipose
tissue expands to accommodate the excessive endogenous
and exogenous lipid synthesized [22, 24]. De novo fatty acid
synthesis is a highly regulated metabolic process and any of
its dysregulation may result in various diseases [22, 25, 26].
An increase in de novo fatty acid synthesis plays an important
role in increased fat mass and is an important contributor
to pathological obesity [4, 22]. Obesity may affect not only
the occurrence of breast cancer but also the prognosis of it,
due to its influence on multiple pathways, such as hormonal
influence, associated adverse disease features, and other yet
unknownmechanisms [17, 21, 27–29].There may be an inter-
relationship between obesity, altered lipid metabolism, and
breast cancer risk, disease occurrence, and progression [4,
17, 21]. Therefore, the prevention of obesity and therapeutic
approach of treating lipid metabolism disorders have risen as
new approaches towards the prevention of breast cancer.
2. FASN as a Target for Cancer Therapy
2.1. Abnormal Fatty Acid Synthesis in Breast Cancer. Fatty
acid is one of the essential substances for mammals [33].
It originates both externally (from a dietary source) and
internally (synthesized by the de novo fatty acid synthesis)
[34–37].The internal sources of fatty acid, its related enzymes,
and its relation to breast cancer tumorigenesis are the focus
of discussions, rather than its external source [38, 39]. Cancer
cells differ from normal cells in several ways [39]. There is
a fundamental difference in the bioenergetic metabolism of
aggressive cancer cells compared to normal cells [39]. Cancer
cells, in order to sustain their high proliferation rates, rely not
only on glycolysis, which is known as the “Warburg Effect”,
but also on an altered lipid metabolism [15, 39]. Whereas
normal cells prefer to utilize exogenous fatty acid from
dietary sources cancer cells utilize a high rate of de novo fatty
acid synthesis independent of dietary fat and independent,
it appears, of hormonal regulation in many cancers, such as
colon cancer and breast cancer [17, 40, 41].The high rate of de
novo synthesis generates essential lipids that are critical for
the formation of cell membrane and produces extra energy
for cancer proliferation and progression [22, 25, 42]. In
contrast to fatty acid synthesis being downregulated in most
normal human tissues, precancerous lesion and cancer cells
upregulate fatty acid synthesis resulting in the high expres-
sion of FASN independent of dietary fat and independent of
hormonal regulation in breast cancer (Figure 1) [17, 43].
2.2. Highly Expressed FASN in Breast Cancer. Research has
shown that FASN is highly expressed in the hepatocytes
and adipocytes of obese patients and in various kinds of
cancer cells [17, 44, 45]. Therefore, targeting FASN has come
to the attention of many in the drug industry due to the
discovery that the inhibition of de novo synthesis of fatty
acid can be used to treat cancer patients [17, 46]. Since the
1980s, researchers have identified FASN in various cancers
including breast cancer, colon cancer, prostate cancer, ovarian
cancer, and endometrium cancer [33, 42, 47]. The afore-
mentioned cancers have shown that the FASN expression
in these cancerous cells is significantly higher than that
in the surrounding normal tissues [48]. Research has also
shown that, through the inhibition of FASN activity or the
reduction of its expression, cancer growth could be effectively
reduced or apoptosis could be induced [23, 49–51]. However,
the underlying mechanism is still under investigation. Some
researchers claim that the inhibition of FASN will reduce the
formation of essential fatty acid that is needed for the growth
of cell membrane and for energy supply, which may be the
cause of cancer cell apoptosis [34, 48, 52–54]. Other research
findings suspect that the rise in Malonyl-CoA concentration
is the trigger for cell apoptosis [53, 55]. Another research has
shown that, after FASN inhibition, the growth of the cancer
cell remains at G0 phase, showing that fatty acid synthesis
is related to cancer cell cycle [46, 56, 57]. In short, the
inhibition of FASNcan effectively andwidely inhibit theDNA
replication of cancer cells and delay the S phase in the cell
cycle, demonstrating that the pathway of fatty acid synthesis
and DNA synthesis activity is related to the growth of cancer
cells [58, 59].
In breast cancer, FASN is found to be highly expressed
in various breast cancer cell lines, including hormone-
independent SKBR3 and hormone-dependent MCF-7 and
ZR-75-1 cells [45, 48, 60]. Among hormone-independent and
hormone-dependent cell lines, hormone-independent breast
cancer cells SKBR3 expressed higher (∼2.5-fold) levels of
FASN compared to hormone-dependent breast cancer cells
[36, 61]. Aside from FASN expression differences between
hormone-dependent and hormone-independent cell lines,
FASN levels also increased with each successive tumor stage
[36]. Research has demonstrated that the inhibition of fatty
acid synthesis induces apoptosis and creates cytotoxicity
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Figure 1: Connecting glucose and lipidmetabolism in normal cells.The high rate of de novo synthesis generates essential lipids that are critical
for the formation of cell membrane and produces extra energy for cancer proliferation and progression. In contrast to fatty acid synthesis
being downregulated inmost normal human tissues, precancerous lesion and cancer cells upregulate fatty acid synthesis, resulting in the high
expression of FASN independent of dietary fat. Fatty acid synthesis also appears to be independent of hormonal regulation in many cancers
including breast cancer. The inhibition of fatty acid synthesis results in the accumulation of the substrate Malonyl-CoA, which can create
cytotoxicity and induce apoptosis. [30, 31].
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which is likely to trigger cell death as a result of the
accumulation of the substrate Malonyl-CoA (Figure 1) [30,
31]. However, scientists have not yet come to the agreement
on the reason why and the specific mechanism by which the
inhibition of fatty acid kills cancer cells [55, 62–64].
2.3. The Structure of FASN. Fatty acid synthase (FASN) is
the key enzyme for de novo fatty acid synthesis and it
catalyzes Acetyl-CoA and Malonyl-CoA to form Palmitate
and 16-carbon long fatty acid [31, 65]. FASN has seven
functional domains, namely, acyl carrier protein (ACP),
Malonyl/acetyltransferase (MAT), ketoacyl synthase (KS),
ketoacyl reductase (KR), dehydrase (DH), enoyl reductase
(ER), and thioesterase (TE) [33, 35, 66]. It can be divided into
two subtypes, types II and I. FASN in bacteria and plants is
type II FASNwith the seven functional domains independent
of one another, which form a multicatalytic function system.
On the other hand, FASN in humans and other mammals
belongs to type I and is encoded by the FASN gene and
composed of two identical 272 kDamultifunctional polypep-
tides, where the seven functional domains form a single
bond [33, 37, 49, 66]. A person with sufficient nutrition who
consumes a balanced diet undergoes little de novo synthesis
of fatty acid. In such case, FASN expression is controlled at
a low level because dietary lipid will provide the fatty acid
needed for normal body functions [25, 42, 47, 54, 58, 67].
FASN has three main functions: energy storage, synthesis of
fat, and lactation [33, 47, 58]. In highly lipogenic tissues, de
novo fatty acid synthesis produces fat from excess carbon
or energy intake and stores it as triglycerides [22, 68]. In a
lactating female, FASN produces medium chain fatty acids
along with thioesterase-II and this enables the baby to easily
digest the milk [34–36]. Under normal conditions, FASN
is regulated by one’s diet and hormones. All carbohydrate
intake, thyroid hormone, insulin, and glucocorticoid can up-
regulate fatty acid synthesis, while unsaturated fatty acid,
cAMP, and glucagon can down-regulate FASN and fatty acid
synthesis [4, 42, 45, 69, 70].
2.4. The Metabolism and Expression of FASN. In the last
decade, numerous studies have focused on the metabolic
alternation of adaptation of cancer cells [71]. Cancer cells
possess the feature of high proliferation differentiation [72].
Cells constantly divide, grow, and absorb external nutrition,
while in themeantime self-synthesizing essential material for
growth [72, 73]. De novo fatty acid synthesis is an important
hallmark of cancer cells setting it apart from normal cells
[42]. Lipids are the main component for the composition of
cell membrane and are essential for cell division [27, 74, 75].
Palmitate is the primary synthesized 16-carbon fatty acid,
from which other forms of lipids are also formed [76]. FASN
is the key enzyme for the synthesis of palmitate and affects
the amount of palmitate formed (Figure 2) [18, 35, 42, 44].
FASN is expressed in most of cancer cells, for example, breast
cancer cells, and has a low expression in normal cells [33, 66].
With de novo fatty acid synthesis, tumor cells endogenously
synthesize extra fatty acid allowing them to sustain higher
proliferation rates and faster growth [25, 77]. Therefore,
targeting fatty acid synthase can be an important strategy for
cancer prevention and treatment.
2.5. Signaling Pathway and Regulation of FASN. The over-
expression of FASN allows for the de novo synthesis of
essential lipids for the formation of cell membrane and
for the production of extra energy via beta-oxidation and
lipid modification of proteins [55, 71, 78]. Although the
mechanisms for tumor related FASN overexpression are still
unclear, two main mechanisms have been proposed. The
first one is the growth factor, which binds to growth factor
receptor, activating their downstream PI3k-Akt and ERK1
(and ERK2) signal transduction pathway (Figure 2) [34, 42,
45, 47, 68]. The FASN expression is regulated by several
growth factors, including epidermal growth factor recep-
tor (EGFR), HER2, steroid hormone, and steroid hormone
receptors (such as ER, PR, and AR) [27, 47, 55, 62, 77].
However, the regulation of FASN expression by these growth
factors is rather complicated. FASN expression and growth
factor-dependent signaling can be coregulated [42, 49, 50].
For example, through downstream PI3K signaling, HER2
regulates FASN expression; meanwhile, reports also demon-
strate that HER2 expression is regulated by FASN expression
[45, 57, 64]. HER2 is an overexpressed gene in cancer cells
[7, 38, 62, 77]. HER2 is the Tyrosine kinase receptor, which
belongs to erbB family [23, 62, 63]. It is similar to the
epithelial growth factor receptor and is also involved with
regulative cell growth and division [62]. HER2 is expressed in
various types of cancer cells [55, 62].Through overexpressing
HER2, cancer cells can produce drug tolerance toward chemo
drugs and are related to poor prognosis in cancer patients.
Recent studies have shown that FASN and HER2 are both
overexpressed in certain types of cancer cells [46, 55, 62, 77].
Inhibiting FASN by either drug or gene silencing can inhibit
HER2 expression; meanwhile, HER2 overexpression leads
to an increase expression of FASN, indicating that there is
a bidirectional regulation mechanism between FASN and
HER2 (Figure 3) [25, 34–36, 79].
Recent studies have shown that FASN expression can
be not only regulated by SPEBT-1c but also controlled by
other transcription factors, such as p53 family proteins and
the lipogenesis-related nuclear protein, SPOT14, which is
overexpressed in breast cancer [25, 47, 79, 80]. The second
mechanism is one whereby steroid hormones binding with
steroid hormone receptors activate similar pathways [35].
These two pathways stimulate FASN expression by the gene
modulation and/or the nuclear maturation of the sterol
regulatory element-binding protein 1c (SREBP1C), which
is a transcription factor that activates FASN by binding
to its promoter region, which contains sterol regulatory
elements [32, 35, 70]. Currently, there are several pathways
that contribute to the initiation of FASN cytotoxicity. One
is where FASN inhibition initiates a more effective apoptosis
in cells with nonfunctioning p53 protein compared to those
cells with functioning p53 protein, which occurs concurrently
with cytostatic response [24, 32, 59, 62]. One is where HER2
overexpressed cells are also linked to FASN induced cytotoxi-
city. In addition, there are studies on ovarian cancer cell lines
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Figure 2: FASN related metabolic and signal transduction pathways. De novo fatty acid synthesis is an important hallmark of cancer cells,
differentiating it fromnormal cells. Palmitate is the primary synthesized 16-carbon fatty acid, fromwhich other lipids are also formed. FASN is
the key enzyme for the synthesis of palmitate and it affects the amount of palmitate formed.The overexpression of FASN allows for the de novo
synthesis of essential lipids for the formation of cellmembrane and for the production of extra energy via beta-oxidation and lipidmodification
of proteins.The binding of the growth factor and the growth factor receptor results in the activation of their downstream PI3k-Akt and ERK1
(and ERK2) signal transduction pathway. The FASN expression is regulated by several growth factors, including epidermal growth factor
receptor (EGFR), HER2, steroid hormone, and steroid hormone receptors (such as ER, PR, andAR). However, there is complicated regulation
of FASN expression by these growth factors. FASN expression and growth factor-dependent signaling are coregulating.
showing that FASN activity modulates Akt activation, and,
at the same time, Akt activation regulates FASN expression,
suggesting that the Akt activation protects cells against FASN
inhibitor induced cell death (Figure 3) [35, 62–64].
2.6. Therapeutic Implication Progress of FASN in Cancer
Treatment, Diagnosis, and Prevention. There are two unique
characteristics of FASN that made it suitable for being an
antitumor target: its tissue distribution and its enzymatic
activities. FASN is highly expressed in breast cancer but not
in nonlactating normal breast tissue [35, 47, 52, 81]. From
the enzymatic activities aspect, it catalyzes the terminal step
of de novo fatty acid synthesis, not affecting other important
components of the lipid metabolism [34, 42, 68]. In addition
to its multienzymatic functions characteristics, it contains
seven catalytic domains that can be targeted, as mentioned
before. Thus, using FASN as a target will influence the prolif-
erating compartment of the breast while the nonproliferating
compartment will remain unaffected [23, 35, 47].
3. Natural Product-Derived FASN Inhibitors
3.1. Single Compound
3.1.1. Single Domain
(1) KS Domain. Currently, there is limited amount of research
on FASN inhibitors. Cerulenin is the first FASN inhibitor
identified and is a natural metabolic product used in antibi-
otics [33, 34, 61, 77]. It is a noncompetitive inhibitor with
FASN and covalently binds with the hydroxyl group on serine
at the end of the KS domain, forming hydroxyl-beta-lactam,
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irreversibly inhibiting de novo fatty acid synthesis [63, 80].
Cerulenin mainly inhibits the synthesis of long chain fatty
acids and only inhibits the growth of cancer cells while the
normal cells remain unaffected [63, 80, 82]. However, the
usage of Cerulenin is limited because of its unstable structure
and high toxicity levels [80, 82, 83].
(2) TE Domain. Other FASN inhibitors that can potentially
be used as cancer treatment drugs have been identified,
such as Orlistat (1-(3-hexyl-4-oxooxetan-2-yl) tridecan-2-yl
2-formamido-4-methylpentanoate), a drug designed to treat
obesity and marketed as a prescription in most countries
[46]. Recent research has shown that Orlistat may also
act on the TE domain of the FASN [46, 48]. Currently,
Orlistat is the only FASN inhibitor under clinical usage.Other
derivatives from Orlistat, such as the beta-lactam derivatives
of Orlistat identified, have shown good inhibitory effect on
FASN activity [46, 48, 49]. Therefore, the development of
Orlistat and its derivatives will be an important approach for
future research on FASN inhibitors.
(3) KRDomain. Epigallocatechin-3-gallate (EGCG), a natural
component of green tea, is one of the several natural plant-
derived polyphenols identified to have an FASN inhibitory
effect higher than that of C75 [83–85]. EGCG acts on the
KR domain of the FASN and is a high micromolar time-
dependent inhibitor [83, 86, 87]. EGCG has a prominent
inhibitory effect because it not only acts on the FASN but also
could inhibit HIF-1-alpha expression by blocking PI3K/Akt
signaling pathway [87]. Recently, EGCG has been developed
as a tumor growth inhibitor and is used in breast cancer
xenograft models. Even so, there are limitations for EGCG
as an FASN inhibitor, and its FASN inhibition effect can
still be improved upon [77, 83, 86, 87]. Prior experiments
have shown that, after the strong acid and heating treatment
of EGCG, FASN inhibition will be greatly increased, and
this raises the possibility that the increased effect is due
to the change in the chemical composition of catechin
[83, 87]. However, the follow-up experiment showed that
EGCG becomes unstable after strong acid and heat treatment
[83, 86, 87]. The initial product is unstable as well, which
makes it difficult to investigate itsmolecular composition and
properties.
Other FASN inhibitors include urea-derived compounds
such as GSK837149A and can specifically inhibit the KR
domain of FASN [88].
3.1.2. Multiple Domains. In 2000, Lotfus and his fellow
colleagues reported a small molecule, a structurally modi-
fied form of Cerulenin to be a novel FASN inhibitor, the
C75 [89]. It is a derivative of 3-carboxy-4-alkyl-2-methyle-
nebutyrolactones that overcomes the toxicity of Cerulenin
and performs a better specific inhibitory effect than Ceru-
lenin [36, 90]. Research has shown that the inhibitory effect
of C75 on FASN differs from that of Cerulenin [36, 49,
77, 90]. C75 inhibits FASN with a noncovalently reversible
inhibition to the KS, ER, and ES domain of FASN [77, 90].
The mechanism, however, by which C75 inhibits cancer cell
growth, is still unclear [80, 90]. In 2000, Kuhajda et al.
demonstrated that C75 inhibits fatty acid synthesis inducing
cancer cell apoptosis; however, more in-depth research is
still needed [36, 81]. Although, compared to other FASN
inhibitors, much research has focused on C75, its clinical
usage is limited due to its unstable nature [77].
3.1.3. Without Inhibitory Target Domain Studies. Icaritin
(ICA), a prenylflavonoid derivative from Epimedium Genus,
can effectively induce SKBr3, ER negative breast cancer cell
line, and cell apoptosis and suppress cell growth in a concen-
tration-dependent manner [91]. Through the FASN/HER2
pathway, ICA is unable to upregulate PEA3 and downregulate
HER2 [91]. This suggests that ICA can be a potent FASN
inhibitor and a potential anticancer drug for future develop-
ment.
Amentoflavone, a natural biflavonoid isolated from S.
tamariscina and abundantly found in the family Selaginel-
laceae, can suppress FASN expression at the protein and
mRNA levels [62, 92]. S. tamariscina has a long history of
being used for the treatment of advanced cancer in TCM
[62, 78], as well as being used as an antioxidant, vasorelaxant,
and anti-HIV and antiangiogenesis agent [62, 78, 93, 94].
In addition, despite amentoflavone’s FASN-inhibitory effect,
which inhibits the translocation of SREBP-1 in SKBR3 cells,
it can suppress HER2 activation and modulate Akt, mTOR,
and JNK phosphorylation [32, 62, 94]. These actions induce
cell death and increase the potential for using amentoflavone
as a chemotherapeutic drug in the prevention or treatment of
HER2-positive breast cancers [78].
3.2. Extract
3.2.1. With Inhibitory Target Domain Studies. Many research-
ers have found that EGCG extracted from grape seeds
has a better inhibiting capacity compared to the effects of
Monomeric catechin and epicatechin on FASN inhibition
explored in previous research [95]. Therefore, the separation
of an active compound of grape seed extract will be mean-
ingful for future studies in terms of its use as a novel FASN
inhibitor, but there aremany steps of extraction that will need
to be further improved [83, 87, 95].Thus, future investigation
and study are needed to confirm the molecular mechanism
of the increased FASN inhibition effect of EGCG as well as
search for the conditions necessary to stabilize the formation
of a high-activity and stable FASN inhibitor.
Coix seed extract from Semen Coicis is an oily substance,
and its main active ingredient is a triglyceride containing
four fatty acids [96]. It is the first drug derived from TCM
to go into clinical trials in the USA and has been proved
to be an effective and safe TCM practice by preclinical
antitumor studies and pharmacokinetics and safety studies
[97]. Yu et al. studied the Coix seed extract’s FASN inhibitory
effect [96, 97]. Their experiment in vitro demonstrated that
Coix seed extract, by inhibiting the KR and ER domain of
FASN, could significantly inhibit FASN activity; in addition,
their experiments in vivo also observed a significant FASN
inhibitory effect in the liver produced by the Coix seed
extract, which was accomplished by elevating LPL and HL
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activity in the plasma as well as affecting the G-6-PD activity
[96, 97]. Thereby, Coix seed extract inhibits fatty acid syn-
thesis and reduces formation of energy supplying tumor cell
growth. Therefore, the antitumor effects of Coix seed extract
are likely to be related to the inhibition of FASN activity
[96, 97]. The study supports that FASN is a novel target
for cancer therapy. Other studies of Coix seed extract show
that it can inhibit tumor cell mitosis at G2/M phases, induce
tumor cell apoptosis, inhibit tumor angiogenesis, and also
upregulate FASN/Apo-1 gene expression and downregulate
Bcl-2 gene expression of tumor cells. In addition, it can
prevent anticancer drug resistance in tumor cells [96, 97].
The present study supports FASN as a novel target for cancer
therapy and provides a theoretical foundation for the clinical
application of Coix seed extract in cancer therapy. Continued
studies are required for the future clinical uses of Coix seed
extract as an FASN inhibiting anticancer drug.
A research by Wang et al. indicates that extracts of
Fallopiamultiflora can both reversibly and irreversibly inhibit
FASN and exhibit a better inhibitory effect than both Ceru-
lenin and C75 [98]. Different than that of C75, which can
only inhibit the KS domain of FASN, Fallopia multiflora
extract can both inhibit the KR and the MT domain [98, 99].
However, due to the complexity of the herbal extract, the
specific analog that exhibits the inhibitory effect has not
yet been identified [99]. Future research is required for a
better understanding of the pharmacological activity and
the inhibitory mechanism in order to develop better FASN
inhibitors in the future. The screening results may provide
direction for future research on novel FASN inhibitors from
these categories of herbal medicines or compounds with
similar chemical structures.
3.3. Only with Basic Inhibitory Effect Screening. Allium
vegetables, represented by Allium fistulosum L., have been
employed for a long time in traditional medical practice to
treat a variety of diseases [100, 101]. In 1998, a case-control
epidemiological study carried out in France suggested that
higher onion intake was a protective factor for breast cancer
[100]. Recently, the anticarcinogenic potential of onion had
been extensively studied by Wang et al. in 2013 [102]. The
study demonstrated that onion extract can inhibit FASN
activity and induce MDA-MB-231 cells [64, 102] apoptosis
as well as reducing intercellular lipid accumulation of 3T3-
L1 adipocytes [102]. This raised the potential of developing
onion into a drug for the prevention and treatment of breast
cancer as well as other obesity-related cancers [100–102].
Nephelium lappaceum L., commonly known as “rambu-
tan”, is a tropical fruit of the Sapindaceae family whose antiox-
idant and antibacterial functions have been used for severe
dysentery or as a carminative in dyspepsia [103, 104]. An
article published in 2011 by Zhao et al. found that Nephelium
lappaceum L. has an FASN inhibitory effect comparable to the
commonly known natural FASN inhibitor EGCG [104]. This
revealed the potential of Nephelium lappaceum L. for being
a promising FASN inhibitor. In addition, isolated glycosides
from Nephelium lappaceum L., the oleane-type triterpene
oligoglycosides, may also be another type of FASN inhibitor
which may be developed into a novel chemoprevention and
chemotherapy drug in the future [103, 104].
There have been years of research on FASN inhibitors and
their role in breast cancer therapy in western medicine and
recently Chinese Medicine has developed a similar research,
with a focus on theweight loss effect of the inhibition of FASN
using herbs [105]. Tian et al. performed a screening of FASN
inhibitor in 31 common herbal medicines and discovered a
number of effective inhibitors in 2004 [105]. Among the 31
herbs, Polygonum multiflorum (何首烏) [106, 107], Alpiniae
officinarum (高良姜), Parasite scurrula (桑寄生), to name
a few, showed strong FASN inhibitory effect and weight loss
effect in animal models [108]. Both Alpiniae officinarum and
Parasite scurrula contain phenols such as flavone, increasing
the potential for polyphenols to be an important active
substance in terms of FASN inhibition [105, 108].
Recent research has screened potential Chinese herbal
medicines for their inhibition effect on fatty acid synthase.
Out of the 225 commonly prescribed herbal medications
screened, 58 of them (25.78%) show strong (80–100%)
inhibitory effect [109]. Among those 58 strong potential
FASN inhibitors, some pure compounds were found includ-
ing alkaloid, anthraquinone, flavonoid (e.g., dried leaf of
Apocynum venetum L. (羅麻布葉), spine of Gleditsia
sinensis (皂角刺), Spatholobus suberectus (雞血藤) [60],
Prunella vulgaris (夏枯草), Scutellaria baicalensis Georgi
(黃芩), hawthorn fruit, and pagodatree flower), phenols,
kaempferol, tannins (e.g., Melaphis chinensis (Bell.) (五倍
子), the root of Sanguisorba officinalis L. (地榆), Rhuen
palmatum L. (大黃), andmature seed of Litchi chinensis Sonn
(荔枝核)), triterpenes, gallic acid, ursolic acid, paeoniflorin,
and saponins [105, 109, 110]. These herbs are characterized,
according to Chinese medicine theory, into those which have
the effects of clearing away heat and toxic materials (Table 1),
enriching the blood and invigorating the circulation of blood
(Table 2), promoting health while promoting meridian and
blood (Table 3), regulating Qi Flow (Table 4), and reducing
phlegm and dehumidification (Table 5) and other effects
(Table 6) including removing blood stasis and promoting
the subsidence of swelling, analgesic, warming spleen and
stomach for dispelling cold, and cooling blood to stop
bleeding by their functions. Linoleic acid [50], some poly-
unsaturated acid [50, 100], polyphenols [108], and flavones
[94], among others, have all shown some FASN inhibitory
effects, with some displaying better inhibiting effects than
C75 [109].
4. Future Perspective and Conclusion
The de novo fatty acid synthesis is a distinct feature of cancer
cells, distinguishing it from normal cells [35].The tumor cell’s
intrinsic properties and the tumor microenvironment result
in the metabolic alternation and adaptation of cancer cells.
This lipid metabolism alternation and the high rate of de
novo fatty acid synthesis allow cancer cells to sustain higher
proliferation rates and rapid growth. Therefore, targeting the
key enzyme of the fatty acid synthesis, the FASN, can be an
important strategy for anticancer drug development.
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Table 1: Herbs with clearing away heat and toxic material functions with strong FASN inhibitory effect. In TCM theory, noxious heat is one of
the underlying pathologies of the occurrence and development of malignancy. Therefore, herbal medicine with detoxification effect plays an
indispensable role in cancer prevention and treatment. With pharmacological studies and analysis of their chemical composition, the herbs
anticancer mechanism mainly includes direct inhibition of tumor-induced apoptosis of tumor cells, regulation of immune function, anti-
inflammatory, detoxification, fever, blocking, and anticarcinogenic mutations. These kinds of herbs are widely used in the clinical treatment
of cancer.
清熱解毒 Clearing away heat and
toxic material Chemical components Pharmacological action
Scutellaria barbata (半枝蓮) Alkaloid; Flavonoid glycoside; Phenol; Steroid;Stearic acid
Antitumor; antimutagenic effect;
diuresis; eliminating phlegm; antivirus
The root of Sanguisorba officinalis L.
(地榆)
triterpenoid saponin Tannins; Sanguisorbin;
A,B,E Gallic acid; Ellagic acid
Antitumor; antibiosis; antiemetic;
hematischesis
The root of Sophora flavescens Ait. (苦
參) Matrine; Oxymatrine; Anagyrine; Flavonoids Antitumor, diuresis, bacteriostat
Glechoma longituba (Nabai) Kupr (金
錢草)
Flavonoids, Quercetin; Choline; glycosides;
Macrolide Antitumor; detumescence; bacteriostat
Prunella vulgaris L. (夏枯草) Flavonoids; Baicalin; Baicalein; Wogonin;Wogonoside
Antitumor, depressurization; diuresis;
antibiosis
The root of Scutellaria baicalensis
Georgi (黃芩) Flavonoids; Baicalin; Baicalein; Wogonin
Antitumor; antibiosis; cholagogue;
hepatoprotective effect
Sophora japonica L. (槐花) Rutin; Triterpenoid Saponin; Flavonoids;Steroids; Tannins
Antitumor; antiulcer; protect blood
vessels; hypolipidemic; anti-inflammation
Table 2: Herbs with promoting blood circulation for removing blood stasis functions with strong FASN inhibitory effect. Stagnation of Qi
and poor blood circulation are recognized as the main pathologies of certain groups of malignancy. This group of herbal medications may
not only induce apoptosis but also improve the antitumor mechanism of a body’s blood circulation, which improves the local hypoxic state,
as well as regulating and promoting immunity.
活血化瘀 Promoting blood
circulation for removing blood stasis Chemical component Pharmacological action
The fruit of Crataegus pinnatifida
Bunge
(山楂)
Crataegolic acid; Chlorogenic acid;
Epicatechin; Epicatechol; Flavonoids Blocking synthesis of nitrosamine
Rosa chinensis Jacq.
(月季花) Gallic acid Antibreast cancer; antithyroid neoplasm
Paeonia veitchii Lynch
(赤芍)
Paeoniflorin; Galloylpaeoniflorin; Paeonol;
Lacioflorin; Catechin Antitumor
Paeonia suffruticosa Andr.
(牡丹皮)
Paeonol; Paeonoside; Paeonolide; Paeoniflorin;
Gallic acid; Phytosterol; Alkaloid
Antitumor; immunoregulation;
bacteriostat
Spatholobus suberectus Dunn
(雞血藤)
Daidzein; Epicatechin; Protocatechuic acid;
Brassicasterol; Stigmasterol; 𝛽-sitosterol;
Auriculatin
Antitumor; bacteriostat
Polygonum cuspidatum Sieb. etc Zucc
(虎杖)
Polydatin; Emodin; Physcion; Chrysophanol;
Citreorsein; Anthraglycside; Resveratrol
Antitumor; immunoregulation; antibiosis;
antivirus; elevation of white blood cell counts
Herba lycopi
(澤蘭)
Essential oils; Flavonoid Glycosides; Saponins;
Phenols; Tannins Antitumor, immunoregulation
4.1. CAM as the Important Trend in Cancer Treatment and
the Superiority of TCM in FASN Inhibitors Development.
Complementary and alternative medicine (CAM) has been a
recent source of drug discovery in cancer research. A wide
range of prescription drugs used for cancer treatment are
derived from medicinal plants and 74% of those drugs were
based on “folk medicine” [111]. Among all CAM modali-
ties, TCM has a long history of clinical practice and well-
established theoretical approaches and also enjoys particular
appreciation for its uses as an adjunct therapy to slow down
the development of chemotherapy drug resistance and to
relieve the unpleasant side effects of chemotherapy and
radiotherapy [60]. However, although TCM is appreciated
for its efficiency and minimal side effect, there is still insuf-
ficient understanding of its mechanism as well as inadequate
evidence for verifying its effectiveness [9, 15, 111]. Although
both the standard cancer therapy and TCM have been used
for decades in China for improving both the clinical outcome
in cancer treatment and the quality of life of the surviving
patients, [11, 111] due to insufficient quality control for herbal
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Table 3:Herbswith promoting health’s functionwith strong FASN inhibitory effect. UnderTCMtheory, theweakness of a healthy atmosphere
in the human body is one of the major underlying pathologies for malignance occurrences. It has been more widely accepted to palliative
therapy without the resection of tumor. This group of herbs is commonly used in combination with chemotherapy and radiotherapy to
improve the patients overall health and increase tolerance of chemotherapy.
扶正培本 Promoting health Chemical components Pharmacological action
The root of Paeonia lactiflora Pall. (白
芍)
Paeoniflorin; Paeonol; Paeonin; Triterpenoids;
Essential oils; Tannins
Antitumor, improve immune function;
composed; analgesia; relieve fever;
anti-inflammation
Cinnamomum cassia Presl (肉桂) Essential oils; Tannins, Mucoid substances;Resins Antitumor, composed; analgesia
Polygonum multiflorumThunb. (何首
烏)
Emodin; Chrysophanol; Rhein; Resveratrol;
Catechin; Epicatechin; Piceid; Gallic acid
Improve immune function; lowering serum
cholesterol; treatment of atherosclerosis
Fructus psoraleae (補骨脂)
Essential oils; Saponins;
Flavonoids; Astragalin; Bavachin;
Monoterpenes; Resin; Stigmasterol;
Antitumor; bacteriostat
Drynaria fortunei (Kunze) J. Sm. (骨碎
補)
Hesperidin; Naringin; Sting-masterol;
Triterpenes
Antitumor; promote bone calcium absorption;
lowering serum cholesterol; composed;
analgesia;
Epimedium brevicornumMaxim. (淫
羊藿)
Icariin; Phytosterol; Essential oils; Cetyl
alcohol; Hentriacontane; Palmitic acid; Stearic
acid; Linolenic acid; Bilobanol; Hyperin;
Tannins
Antitumor; antibechic; enhance sexual
function
Cynomorium ongaricum Rupr. (鎖陽) Tannins; Anthocyanin;Triterpenoid saponin Enhance immune function; demulcent
Carica papaya L. (番木瓜) Papain; Carica; Rennet; Carotene Inhibition of tumor growth
Eclipta prostrata L. (墨旱蓮) Tannins; Essential oils; Saponins; Ecliptine Hematischesis
Table 4: Herbs with regulatingQi flow’s functionwith strong FASN inhibitory effect.The stagnation of Qi, one of themost importantmaterial
bases in human body according to TCM theory, will result in a lot of different diseases including malignancy. Therefore, regulating the Qi
flow is an important strategy in diseases treatment and in malignancy treatments; this group of herbs is usually used in combination with
those stated in Tables 2 and 3.
理氣 Regulating QI flow Chemical components Pharmacological action
Illicium verumHook. f. (八角茴香) Fatty oils; Anise oil; Resin; Quercetin;Kaempferol
Antitumor; elevation of white blood cells;
bacteriostat; promote digestion
Lindera strychnifolia (Sieb. et Zucc.)
F.-Vill (烏藥)
Essential oils; borneol; Furan sesquiterpene;
Alkaloid; Neolinderalactone; Linderane
Antitumor; promote intestinal peristalsis;
promote the secretion of digestive juice;
antibiosis
Rosa rugosaThunb. (玫瑰花) Essential oils; Citronellol; Vernol; Phenylethylacetate; Isoquercitrin; Tannins; Gallic acid Antitumor; immunoregulation
Fructus Amomi (砂仁) Bomyl acetate; Camphor; Limonene; nerolidol;Cineole; Flavonoids Antitumor; bacteriostat
Areca catechu L. (檳榔)
Tannins; Alkaloid; Arecoline; Arecaidine;
Catechin; Epicatechin; Myristic acid; Lauric
acid; Palmitic acid; Oleic acid; Linoleic acid
Antitumor; expelling parasite; antiviral;
antifungal
products and the shortage of randomized controlled trials
(RCT), whether herbal medicines can indeed treat cancer
remains controversial [10–12, 15].
Statistics have shown that out of the 260,000 to 300,
000 plant species in the world, only around 5,000 of them
have been studied for their possible medical applications
[15]. With the long history of clinical based practice of
Chinese herbal medicine and great number of histological
document and case reports in cancer treatment, Chinese
herbal medicine has a unique position in drug discovery
for molecular targeting based therapeutic strategy [9–11, 15].
The research done on FASN inhibitors is receiving increasing
amounts of attention from the media, since it was reported
as a potential therapeutic target for both obesity and breast
cancer. This has raised the question of whether there are any
potent FASN inhibitors in Chinese herbal medicine or in any
other natural product.The ongoing development of the FASN
inhibitors screening strategy will provide a good platform
for exploring and discovering inhibitors in natural products,
which are more molecular target specific and contain lower
toxicity levels. Chinese herbal medicine with its multiple
active components is considered a promising source for the
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Table 5: Herbs with reducing phlegm and dehumidification functions with strong FASN inhibitory effect. Phlegm in the body can be not
only the pathological product of the body but also a risk factor for tumor development. This group of herbs can relieve symptoms caused by
the tumor and have antitumor effects.
化痰去濕 Reduce phlegm and
dehumidification Chemical components Pharmacological action
Uncaria gambier Roxb. (兒茶)
Catechu-tannic acid; Catechin; Epicatechin;
Phlobatannin; Quercetin; Kaempferol;
Afzelechin; Aflatoxin
Inhibition of cancer cell growth; elevation of
white blood cells
Pyrrosia lingua (Thunb) Farw. (石葦) Diploptene; saponins; Anthraquinone;Flavonoids; Antitumor; hematischesis; diuresis
Gleditsia sinensis Lam. (皂角刺) Flavonoids; Phenol; Fustin; Fisetin Antitumor
Eriobotrya japonica (Thunb.) Lindl. (枇杷
葉)
Nitrilosides; Farnesol; Amygdalin; Citric acid;
Oleanolic Acid; Eugeniin; Tannins Antitumor; reduce phlegm;
Morus alba L. (桑白皮) Flavonoids; Mulberrin; Morusin; Palmitic acid;Essential oils
Inhibition of the growth of tumor; diuresis;
detumescence
Table 6: Herbs with other functions with strong FASN inhibitory effect. This group of herbs is commonly used and seen in the prescription
for malignancy treatment depending on the patient’s symptoms.
其他 Others Chemical components Pharmacological action
Rhuem palmatum L.
(大黃)
Puerarin; Chrysophaein; Chrysophanol; Rhein;
Gallic acid; Tannins; Catechin
Antitumor; inhibition of the growth of
tumor
Melaphis chinensis (Bell.)
(五倍子) Gallotannin; gallic acid Antitumor; hematischesis; detoxification
Artemisia argyi Levl. et Vant.
(艾葉) Essential oils; oil of eucalyptus; Camphor
Antitumor; enhance immune function;
bacteriostasis; virus inhibition
Tetradium ruticarpum
(吳茱萸)
Evodiamine; Rutaecarpine; Limonin;
Synephrine Antitumor; bacteriostat; analgesia
Ramulus Cinnamomi
(桂枝)
Cinnamaldehyde; Benzylbenzoate;
Cinnamylacetate; Calamenene; Coumarin Antitumor; antivirus; antibiosis; relieve fever
Rhizoma Alpiniae Officinarum
(高良姜)
Curcumin; Dihydrocurcumin; Galangin;
Quercetin; Kaempferol; Kaempferide;
Quercetin; Essential oils
Antitumor; antibiosis
design of drugs that regulatemultiple cellular signal pathways
for cancer therapy. This leads us into a new era or anticancer
drug development.
4.2. Future Potential of FASN Inhibitors in Cancer Treatment.
As mentioned before, molecular targeted therapy has been
attracting considerable attention in the research of cancer
treatment. An ideal molecular target should be preferentially
expressed or activated in malignant cells but not in normal
cells, thus making FASN an attractive target for future
research. With the progress of molecular and genetic tech-
nologies, a number of target inhibitors have been discovered
either by synthesis or design. In FASN specific inhibition, C75
and EGCG are well known examples of inhibitors. However,
their therapeutic efficacies are limited due to either their high
toxic level or unstable nature.Therefore, seeking amore stable
and potent drug as a target inhibitor will be an important
future trend for research and development for oncologists.
In the future research for potential FASN inhibitors, there
should be two main approaches: the first is to screen for
individual herbal medicines and their active compounds and
the other is to screen for traditional formulas or effective
clinical experience-based formulas under the guidance of
either TCM theory or modern pharmacology [9, 12]. On
the basis of the theory of traditional Chinese medicine, the
treatment of breast cancer with a focus on weight loss effect
can follow two approaches: by smoothing liver and regulating
Qi and by promoting blood circulation for removing blood
stasis. Therefore, further research on herbal medicines and
traditional formulas may be a promising method for the
development of more potent anticancer drugs.
Over the past few decades, active compounds extracted
from herbal medicines have received good responses clin-
ically. The investigation of Chinese Herbal Medicine with
weight loss effects, which may be related to inhibition of
the fatty acid synthesis pathway, may be an advantageous
approach for future research. It is worthwhile to investi-
gate those herbal medicines commonly used in Traditional
Prescription for antibreast cancer treatment as well, such
as the root of Sanguisorba officinalis L. (地榆), Spatholobus
suberectus (雞血藤), Pericarpium granati (石榴皮), the root
of Paeonia lactiflora Pall. (白芍), Paeonia vaitchii Lynch
(赤芍), and Paeonia suffruticosa Andr. (牡丹皮). Further
studies on the inhibitory mechanisms and domains of these
medicines, with their relatively good FASN inhibitory effect,
will provide us with a much better understanding of cancer
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Table 7: TCM prescriptions with potential FASN inhibitory effect. Among these six commonly used antitumor prescriptions, all of them
contain herbs with FASN inhibitory effect. Although studies have shown the antitumor effect of these prescriptions, a lack of studies have
been carried out investigating their pharmacological actions and the underlying mechanisms.
Number Name of the Prescription Composition Effect
1 Chaihu Shugan Powder(柴胡疏肝散)
Pericarpium Citri reticulatae (陳皮); Root of Chinese
thorowax (柴胡); Rhizoma Ligustici (川芎); Fructus
Aurantii (枳殼);
The root of Paeonia lactiflora Pall. (芍藥); Radix
glycyrrhizae Preparata (炙甘草); Rhizoma cyperi (香附)
1. Smoothing Liver and
Regulating Qi
2. Invigorating Blood
Circulation and Alleviate
Pain
2 Taoren Chengqi Decoction(桃核承氣湯)
Semen persicae (桃仁); Radix glycyrrhiza (甘草);
Mirabilite (芒硝); Rhuen palmatum L. (大黃);
Ramulus Cinnamomi (桂枝)
Promoting Blood
Circulation for Removing
Blood Stasis
3 Fuyuan Huoxue Decoction(復元活血湯)
Root of Chinese Thorowax (柴胡); Radix Trichosanthis
(瓜蔞根); Chinese angelica (當歸); Flos carthami (紅
花); Radix Glycyrrhizae (甘草); Squama manis (穿山
甲); Rhuen palmatum L. (大黄); Semen Persicae (桃
仁)
Promoting Blood
Circulation for Removing
Blood Stasis
4 Xuefu Zhuyu Decoction(血府逐瘀湯)
Chinese angelica (當歸); Rehmannia glutinosa Libosch
(生地); Semen persicae (桃仁); Flos carthami (紅花);
Fructus Aurantii (枳殼); Paeonia vaitchii Lynch (赤
芍); Root of Chinese thorowax (柴胡); Radix
glycyrrhizae (甘草); Platycodon grandiforus (桔梗);
Rhizoma ligustici Chuanxiong (川芎); Radix
Achyranthis bidentatae (牛膝)
1. Promoting Blood
Circulation for Removing
Blood Stasis
2. Promoting the Qi
Circulation and Stopping
Pain
5 Wenjing Decoction(溫經湯)
Tetradium ruticarpum (吳茱萸); Chinese angelica (當
歸); Rhizoma Ligustici Chuanxiong (川芎) The root of
Paeonia lactiflora Pall. (芍藥); Panax ginseng C. A.
Mey. (人參); Ramulus Cinnamomi (桂枝); Colla Corii
Asini (阿膠) Paeonia suffruticosa Andr. (牡丹皮);
Zingiber officinale (生薑); Radix glycyrrhizae (甘草);
Pinellia ternata (半夏); Radix ophiopogonis (麥門冬)
1. Promoting Blood
Circulation for Removing
Blood Stasis
2. Warming Channel for
Dispelling Cold
6 Xiaoyao Powder(逍遙散)
Root of Chinese thorowax (柴胡); Chinese angelica (當
歸); The root of Paeonia lactiflora Pall. (白芍);
Atractylodes macrocephala (白術);Wolfiporia cocos (茯
苓); Rhizoma Zingiberis Recens (生薑);Mentha
haplocalyx (薄荷); Radix glycyrrhizae Preparat (炙甘
草)
1. Smoothing Liver and
Regulating Qi
2. Promoting Blood
Circulation for Removing
Blood Stasis
In Composition, Herbal Medicines with the screening of FASN inhibitory effect are bolded.
biology and equip us with the knowledge needed for better
future implementation for future cancer chemotherapy and
chemoprevention.
Currently, all of the basic screenings have only focused
on the FASN inhibitory effect of one single herbal medicine.
However, clinically, most of the Chinese herbal medications
are prescribed as a combination of a number of herbal medi-
cines, in the form of a decoction. There is limited research
on the FASN inhibitory effect of TCM herbal decoctions.
Some decoctions commonly prescribed to breast cancer
patients have been found to be composed of several herbal
medicines that have proven FASN inhibitory effects. As
mentioned before, smoothing liver and regulating Qi and
promoting blood circulation for removing blood stasis are
two main ways to treat breast cancer under the guidance
of TCM theory. Herein, we will give one example of TCM
prescription with the effect of smoothing liver and regulating
Qi (Tables 7-1); four examples (Tables 7-2,3,4,5)with the effect
of promoting blood circulation for removing blood stasis; and
one example with both of these two effects (Tables 7-6).
4.3. Conclusion. Unlike surgery, chemotherapy, and radio-
therapy, which can have serious consequence on the human
body, the practice and usage of Chinese herbal medicine in
cancer therapy mobilize and regulate the body’s functions,
enhancing the body’s ability to fight cancer. Therefore, Chi-
nese herbal medicine may be more suitable for inoperable
patients with advanced cancer, for those in intermittent
periods of chemotherapy, or for patients in a postoperative
recovery period. There has been an increase of attention on
the research of Chinese herbal medicine in the prevention
of cancer and inhibition of cancer metastasis. There is an
impressive renaissance seeking for semisynthetic drugs or
derivatives from natural compounds. Progress in this regard
not only adds to the Chemical Bank but also leads to a
better understanding of the chemical basis of Chinese herbal
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medicine for the treatment of cancer using drugs obtained
from natural sources.
Abbreviations
FASN: Fatty acid synthase
TCM: Traditional chinese medicine
CAM: Complementary and alternative medicine
BMI: Body mass index
EGCG: Epigallocatechin gallate
EGFR: Epidermal growth factor receptor
SREBP1C: Sterol regulatory element-binding protein
1c.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The authors thank Wujing Zhang from the University of
Southern California and Emille Kohl from the University of
Hong Kong for editorial assistance. The work was supported
by the Seed Funding Programme for Basic Research, Univer-
sity of Hong Kong (104001763).
References
[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and
D. Forman, “Global cancer statistics,” CA Cancer Journal for
Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
[2] P. Boyle and B. Levin,World Cancer Report, IARC Press, Lyon,
France, 2008.
[3] R. Alteri, C. Barnes, A. Burke et al., American Cancer Society.
Breast Cancer Facts & Figures 2013-2014, American Cancer
Society, 2013.
[4] A. R. Carmichael and T. Bates, “Obesity and breast cancer: a
review of the literature,” Breast, vol. 13, no. 2, pp. 85–92, 2004.
[5] H. D. Nelson, B. Zakher, A. Cantor et al., “Risk factors for breast
cancer for women aged 40 to 49 years: a systematic review and
meta-analysis,” Annals of Internal Medicine, vol. 156, no. 9, pp.
635–648, 2012.
[6] A. Montazeri, J. Sadighi, F. Farzadi et al., “Weight, height, body
mass index and risk of breast cancer in postmenopausal women:
a case-control study,” BMC Cancer, vol. 8, article 278, 2008.
[7] Agilent Technologies Affymetrix, Applied Biosystems, AstraZe-
neca, Novartis Oncology, Pfizer, and Roche Diagnostics, “The
Third International Symposium on the Molecular Biology of
Breast Cancer,” Breast Cancer Research, vol. 7, supplement 2, pp.
S1–S62, 2005.
[8] E. Ernst, “Complementary and alternativemedicine (CAM) and
cancer: the kind face of complementary medicine,” Interna-
tional Journal of Surgery, vol. 7, no. 6, pp. 499–500, 2009.
[9] W. L. W. Hsiao and L. Liu, “The role of traditional Chinese
herbalmedicines in cancer therapy fromTCMtheory tomecha-
nistic insights,” PlantaMedica, vol. 76, no. 11, pp. 1118–1131, 2010.
[10] J.-J. Li, J.-P. Fu, and J. T. Li, “Chinese medicine approach in
clinical practice for breast cancer survivors,” Chinese Journal of
Integrative Medicine, vol. 4, pp. 308–315, 2011.
[11] S.-Y. Pan, S.-B. Chen, H.-G. Dong et al., “New perspec-
tives on chinese herbal medicine (Zhong-Yao) research and
development,” Evidence-Based Complementary and Alternative
Medicine, vol. 2011, Article ID 403709, 2011.
[12] S. Wang, S. Penchala, S. Prabhu, J. Wang, and Y. Huang,
“Molecular basis of traditional chinese medicine in cancer
chemoprevention,” Current Drug Discovery Technologies, vol. 7,
no. 1, pp. 67–75, 2010.
[13] D. J. Newman, G. M. Cragg, and K. M. Snader, “Natural
products as sources of new drugs over the period 1981–2002,”
Journal of Natural Products, vol. 66, no. 7, pp. 1022–1037, 2003.
[14] S. Miller, J. Stagl, D. B. Wallerstedt, M. Ryan, and P. J. Mansky,
“Botanicals used in complementary and alternative medicine
treatment of cancer: clinical science and future perspectives,”
Expert Opinion on Investigational Drugs, vol. 17, no. 9, pp. 1353–
1364, 2008.
[15] Z. Wang, N. Wang, J. Chen, and J. Shen, “Emerging glycolysis
targeting and drug discovery from chinese medicine in can-
cer therapy,” Evidence-Based Complementary and Alternative
Medicine, vol. 2012, Article ID 873175, 13 pages, 2012.
[16] X. F. Zhai, Z. Chen, B. Li et al., “Traditional herbal medicine
in preventing recurrence after resection of small hepatocellular
carcinoma: a multicenter randomized controlled trial,” Journal
of Integrative Medicine, vol. 11, pp. 90–100, 2013.
[17] M. J. Khandekar, P. Cohen, and B. M. Spiegelman, “Molecular
mechanisms of cancer development in obesity,” Nature Reviews
Cancer, vol. 11, no. 12, pp. 886–895, 2011.
[18] Y. Shi and P. Burn, “Lipid metabolic enzymes: emerging drug
targets for the treatment of obesity,” Nature Reviews Drug
Discovery, vol. 3, no. 8, pp. 695–710, 2004.
[19] R. Ballard-Barbash, S. Hunsberger,M.H. Alciati et al., “Physical
activity, weight control, and breast cancer risk and survival:
clinical trial rationale and design considerations,” Journal of the
National Cancer Institute, vol. 101, no. 9, pp. 630–643, 2009.
[20] S. E. Zagami, N. Golmakani, F. H. Shandiz, and A. Saki,
“Evaluating the relationship between body size and body shape
with the risk of breast cancer,” Oman Medical Journal, vol. 28,
pp. 389–394, 2013.
[21] X. L. Wang, C. X. Jia, L. Y. Liu, Q. Zhang, Y. Y. Li, and L. Li,
“Obesity, diabetes mellitus, and the risk of female breast cancer
in Eastern China,” World Journal of Surgical Oncology, vol. 11,
article 71, 2013.
[22] L. Garrido-Sa´nchez, J. Vendrell, D. Ferna´ndez-Garc´ıa et al., “De
novo lipogenesis in adipose tissue is associated with course of
morbid obesity after bariatric surgery,” PLoS ONE, vol. 7, no. 2,
Article ID e31280, 2012.
[23] R. Lupu and J. A. Menendez, “Targeting fatty acid synthase
in breast and endometrial cancer: an alternative to selective
estrogen receptor modulators?” Endocrinology, vol. 147, no. 9,
pp. 4056–4066, 2006.
[24] M. S. Strable and J. M. Ntambi, “Genetic control of de novo
lipogenesis: role in diet-induced obesity,” Critical Reviews in
Biochemistry and Molecular Biology, vol. 45, no. 3, pp. 199–214,
2010.
[25] T. Mashima, H. Seimiya, and T. Tsuruo, “De novo fatty-acid
synthesis and related pathways as molecular targets for cancer
therapy,” British Journal of Cancer, vol. 100, no. 9, pp. 1369–1372,
2009.
[26] Q. Chen and Y. Zhang, “Effect of functional factors in the hull
of camellia oleifera abel. On obesity and dyslipidemia,” China
Academic Journal, 2011.
14 Evidence-Based Complementary and Alternative Medicine
[27] B. P. Atshaves, G. G. Martin, H. A. Hostetler, A. L. McIntosh, A.
B. Kier, and F. Schroeder, “Liver fatty acid-binding protein and
obesity,” Journal of Nutritional Biochemistry, vol. 21, no. 11, pp.
1015–1032, 2010.
[28] Z. Suba, “Circulatory estrogen level protects against breast
cancer in obese women,” Recent Patents on Anti-Cancer Drug
Discovery, vol. 8, pp. 154–167, 2013.
[29] J. S. Varghese, D. J. Thompson, K. Michailidou et al., “Mammo-
graphic breast density and breast cancer: evidence of a shared
genetic basis,” Cancer Research, vol. 72, no. 6, pp. 1478–1484,
2012.
[30] E. S. Pizer, J. Thupari, W. F. Han et al., “Malonyl-coenzyme-
A is a potential mediator of cytotoxicity induced by fatty-
acid synthase inhibition in human breast cancer cells and
xenografts,” Cancer Research, vol. 60, no. 2, pp. 213–218, 2000.
[31] W. Zhou, Y. Tu, P. J. Simpson, and F. P. Kuhajda, “Malonyl-
CoA decarboxylase inhibition is selectively cytotoxic to human
breast cancer cells,” Oncogene, vol. 28, no. 33, pp. 2979–2987,
2009.
[32] X. Zhao, D. Feng, Q. Wang et al., “Regulation of lipogenesis
by cyclin-dependent kinase 8-mediated control of SREBP-1,”
Journal of Clinical Investigation, vol. 122, pp. 2417–2427, 2012.
[33] F. J. Asturias, J. Z. Chadick, I. K. Cheung et al., “Structure
and molecular organization of mammalian fatty acid synthase,”
Nature Structural and Molecular Biology, vol. 12, no. 3, pp. 225–
232, 2005.
[34] A. Jayakumar, M.-H. Tai, W.-Y. Huang et al., “Human fatty acid
synthase: properties and molecular cloning,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 92, no. 19, pp. 8695–8699, 1995.
[35] F. P. Kuhajda, “Fatty acid synthase and cancer: new application
of an old pathway,” Cancer Research, vol. 66, no. 12, pp. 5977–
5980, 2006.
[36] F. P. Kuhajda, E. S. Pizer, J. N. Li, N. S. Mani, G. L. Frehywot,
and C. A. Townsend, “Synthesis and antitumor activity of an
inhibitor of fatty acid synthase,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 97, no.
7, pp. 3450–3454, 2000.
[37] S. S. Chirala and S. J. Wakil, “Structure and function of animal
fatty acid synthase,” Lipids, vol. 39, no. 11, pp. 1045–1053, 2004.
[38] J. W. Clendening and L. Z. Penn, “Targeting tumor cell
metabolism with statins,” Oncogene, vol. 31, pp. 4967–4978,
2012.
[39] R. J. DeBerardinis, “Is cancer a disease of abnormal cellular
metabolism? New angles on an old idea,” Genetics in Medicine,
vol. 10, no. 11, pp. 767–777, 2008.
[40] E. S. Pizer, F. D. Wood, H. S. Heine, F. E. Romantsev, G. R.
Pasternack, and F. P. Kuhajda, “Inhibition of fatty acid synthesis
delays disease progression in a xenograft model of ovarian
cancer,” Cancer Research, vol. 56, no. 6, pp. 1189–1193, 1996.
[41] Q. Fu,W. Cai,M.Wang, and Y.Wang, “Effects of inhibiting fatty
acid synthase on the growth of colorectal cancer cells and its
mechanism,” Chinese Journal of Gastroenterology, vol. 7, no. 4,
pp. 202–205, 2002.
[42] J. A. Menendez and R. Lupu, “Fatty acid synthase and the
lipogenic phenotype in cancer pathogenesis,” Nature Reviews
Cancer, vol. 7, no. 10, pp. 763–777, 2007.
[43] A. Georgiadi and S. Kersten, “Mechanisms of gene regulation
by fatty acids,” Advances in Nutrition, vol. 3, pp. 127–134, 2012.
[44] I. Kelesidis, T. Kelesidis, and C. S. Mantzoros, “Adiponectin and
cancer: a systematic review,” British Journal of Cancer, vol. 94,
no. 9, pp. 1221–1225, 2006.
[45] F. P. Kuhajda, “AMP-activated protein kinase and human
cancer: cancer metabolism revisited,” International Journal of
Obesity, vol. 32, no. 4, pp. S36–S41, 2008.
[46] J. A. Menendez, L. Vellon, and R. Lupu, “Antitumoral actions
of the anti-obesity drug orlistat (Xenical™) in breast cancer
cells: blockade of cell cycle progression, promotion of apoptotic
cell death and PEA3-mediated transcriptional repression of
Her2/neu (erbB-2) oncogene,” Annals of Oncology, vol. 16, no.
8, pp. 1253–1267, 2005.
[47] S. S. Chirala, A. Jayakumar, Z.-W. Gu, and S. J. Wakil, “Human
fatty acid synthase: role of interdomain in the formation of
catalytically active synthase dimer,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 98, no.
6, pp. 3104–3108, 2001.
[48] H.-Y. Chuang, Y.-F. Chang, and J.-J. Hwang, “Antitumor effect
of orlistat, a fatty acid synthase inhibitor, is via activation
of caspase-3 on human colorectal carcinoma-bearing animal,”
Biomedicine and Pharmacotherapy, vol. 65, no. 4, pp. 286–292,
2011.
[49] R. Flavin, S. Peluso, P. L. Nguyen, and M. Loda, “Fatty acid
synthase as a potential therapeutic target in cancer,” Future
Oncology, vol. 6, no. 4, pp. 551–562, 2010.
[50] S. K. Kachhap, P. P. Dange, R. H. Santani, S. S. Sawant, and S.
N. Ghosh, “Effect of 𝜔-3 fatty acid (docosahexanoic acid) on
BRCA1 gene expression and growth in MCF-7 cell line,” Cancer
Biotherapy and Radiopharmaceuticals, vol. 16, no. 3, pp. 257–
263, 2001.
[51] M. Wu, K. A. Harvey, N. Ruzmetov et al., “Omega-3 polyun-
saturated fatty acids attenuate breast cancer growth through
activation of a neutral sphingomyelinase-mediated pathway,”
International Journal of Cancer, vol. 117, no. 3, pp. 340–348, 2005.
[52] A. Vazquez-Martin, S. Ropero, J. Brunet, R. Colomer, and
J. A. Menendez, “Inhibition of Fatty Acid Synthase (FASN)
synergistically enhances the efficacy of 5-fluorouracil in breast
carcinoma cells,” Oncology reports, vol. 18, no. 4, pp. 973–980,
2007.
[53] E. S. Pizer, F. J. Chrest, J. A. DiGiuseppe, and W. F. Han,
“Pharmacological inhibitors of mammalian fatty acid synthase
suppress DNA replication and induce apoptosis in tumor cell
lines,” Cancer Research, vol. 58, no. 20, pp. 4611–4615, 1998.
[54] G. Gago, L. Diacovich, A. Arabolaza, S.-C. Tsai, and H.
Gramajo, “Fatty acid biosynthesis in actinomycetes,” FEMS
Microbiology Reviews, vol. 35, no. 3, pp. 475–497, 2011.
[55] A. Vazquez-Martin, R. Colomer, J. Brunet, and J. A. Menen-
dez, “Pharmacological blockade of fatty acid synthase (FASN)
reverses acquired autoresistance to trastuzumab (Herceptin by
transcriptionally inhibiting “HER2 super-expression” occur-
ring in high-dose trastuzumab-conditioned SKBR3/Tzb100
breast cancer cells,” International Journal of Oncology, vol. 31,
no. 4, pp. 769–776, 2007.
[56] S. Lu, G. Yu, Y. Zhu, and M. C. Archer, “Cyclooxygenase-
2 overexpression in MCF-10F human breast epithelial cells
inhibits proliferation, apoptosis and differentiation, and causes
partial transformation,” International Journal of Cancer, vol. 116,
no. 6, pp. 847–852, 2005.
[57] W. Zhou, P. J. Simpson, J. M. McFadden et al., “Fatty acid
synthase inhibition triggers apoptosis during S phase in human
cancer cells,” Cancer Research, vol. 63, no. 21, pp. 7330–7337,
2003.
[58] V. Fritz and L. Fajas, “Metabolism and proliferation share com-
mon regulatory pathways in cancer cells,”Oncogene, vol. 29, no.
31, pp. 4369–4377, 2010.
Evidence-Based Complementary and Alternative Medicine 15
[59] S. M. Hadad, D. G. Hardie, V. Appleyard, and A. M.Thompson,
“Effects of metformin on breast cancer cell proliferation, the
AMPK pathway and the cell cycle,” Clinical and Translational
Oncology, 2013.
[60] Z.-Y.Wang, D.-M.Wang, T. Y. Loo et al., “Spatholobus suberec-
tus inhibits cancer cell growth by inducing apoptosis and
arresting cell cycle at G2/M checkpoint,” Journal of Ethnophar-
macology, vol. 133, no. 2, pp. 751–758, 2011.
[61] Y. Y. Wang, F. P. Kuhajda, J. Li et al., “Fatty acid synthase as
a tumor marker: its extracellular expression in human breast
cancer,” Journal of ExperimentalTherapeutics and Oncology, vol.
4, no. 2, pp. 101–110, 2004.
[62] J. S. Lee, J. Y. Sul, J. B. Park et al., “Fatty acid synthase inhibition
by amentoflavone suppresses HER2/neu (erbB2) oncogene in
SKBR3 human breast cancer cells,” Phytotherapy Research, vol.
27, pp. 713–720, 2013.
[63] J. A.Menendez, I. Mehmi, V. A. Verma, P. K. Teng, and R. Lupu,
“Pharmacological inhibition of fatty acid synthase (FAS): a
novel therapeutic approach for breast cancer chemoprevention
through its ability to suppress Her-2/neu (erbB-2) oncogene-
induced malignant transformation,” Molecular Carcinogenesis,
vol. 41, no. 3, pp. 164–178, 2004.
[64] P. D. Schley, H. B. Jijon, L. E. Robinson, and C. J. Field,
“Mechanisms of omega-3 fatty acid-induced growth inhibition
in MDA-MB-231 human breast cancer cells,” Breast Cancer
Research and Treatment, vol. 92, no. 2, pp. 187–195, 2005.
[65] W.-X. Tian, R.-F. Jiang, H.-B. Wu, Y.-H. Shi, and Y.-H. Wang,
“The substrate inhibition by NADPH and kinetics of fatty acid
synthase from duck liver,” Chinese Biochemical Journal, vol. 10,
no. 4, pp. 413–419, 1994.
[66] T.Maier, S. Jenni, andN. Ban, “Architecture ofmammalian fatty
acid synthase at 4.5 a˚ resolution,” Science, vol. 311, no. 5765, pp.
1258–1262, 2006.
[67] J. A. Menendez, R. Colomer, and R. Lupu, “Why does tumor-
associated fatty acid synthase (oncogenic antigen-519) ignore
dietary fatty acids?”Medical Hypotheses, vol. 64, no. 2, pp. 342–
349, 2005.
[68] L. Eissing, T. Scherer, K. Todter et al., “De novo lipogenesis in
human fat and liver is linked to ChREBP-beta and metabolic
health,” Nature Communications, vol. 4, p. 1528, 2013.
[69] A. Rinke, H.-H. Mu¨ller, C. Schade-Brittinger et al., “Placebo-
controlled, double-blind, prospective, randomized study on
the effect of octreotide LAR in the control of tumor growth
in patients with metastatic neuroendocrine midgut tumors:
a report from the PROMID study group,” Journal of Clinical
Oncology, vol. 27, no. 28, pp. 4656–4663, 2009.
[70] A. T. Willingham, Q. L. Deveraux, G. M. Hampton, and P. Aza-
Blanc, “RNAi and HTS: exploring cancer by systematic loss-of-
function,” Oncogene, vol. 23, no. 51, pp. 8392–8400, 2004.
[71] R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer
cell metabolism,” Nature Reviews Cancer, vol. 11, no. 2, pp. 85–
95, 2011.
[72] T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem
cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859,
pp. 105–111, 2001.
[73] D. A. Tennant, R. V. Dura´n, and E. Gottlieb, “Targeting
metabolic transformation for cancer therapy,” Nature Reviews
Cancer, vol. 10, no. 4, pp. 267–277, 2010.
[74] I. J. Lodhi, X. Wei, and C. F. Semenkovich, “Lipoexpediency:
De novo lipogenesis as a metabolic signal transmitter,” Trends
in Endocrinology and Metabolism, vol. 22, no. 1, pp. 1–8, 2011.
[75] F. Podo, “Tumour phospholipid metabolism,” NMR in
Biomedicine, vol. 12, pp. 413–439, 1999.
[76] M.Hilvo, S. Gade, T. Hyotylainen et al., “Monounsaturated fatty
acids in serum triacylglycerols are associated with response to
neoadjuvant chemotherapy in breast cancer patients,” Interna-
tional Journal of Cancer, vol. 134, no. 4, pp. 1725–1733, 2013.
[77] T. Puig, A. Va´zquez-Mart´ın, J. Relat et al., “Fatty acid
metabolism in breast cancer cells: differential inhibitory effects
of epigallocatechin gallate (EGCG) and C75,” Breast Cancer
Research and Treatment, vol. 109, no. 3, pp. 471–479, 2008.
[78] J. S. Lee, M. S. Lee, W. K. Oh, and J. Y. Sul, “Fatty acid
synthase inhibition by amentoflavone induces apoptosis and
antiproliferation in human breast cancer cells,” Biological and
Pharmaceutical Bulletin, vol. 32, no. 8, pp. 1427–1432, 2009.
[79] F. P. Kuhajda, K. Jenner, F. D.Wood et al., “Fatty acid synthesis: a
potential selective target for antineoplastic therapy,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 91, no. 14, pp. 6379–6383, 1994.
[80] A. Kawaguchi, H. Tomoda, S. Nozoe, S. Omura, and S. Okuda,
“Mechanism of action of cerulenin on fatty acid synthetase:
effect of cerulenin on iodoacetamide-induced malonyl-coa
decarboxylase activity,” Journal of Biochemistry, vol. 92, no. 1,
pp. 7–12, 1982.
[81] F. P. Kuhajda, “Fatty-acid synthase and human cancer: new
perspectives on its role in tumor biology,” Nutrition, vol. 16, no.
3, pp. 202–208, 2000.
[82] J. N.Thupari, M. L. Pinn, and F. P. Kuhajda, “Fatty acid synthase
inhibition in human breast cancer cells leads to malonyl-CoA-
induced inhibition of fatty acid oxidation and cytotoxicity,”
Biochemical and Biophysical Research Communications, vol. 285,
no. 2, pp. 217–223, 2001.
[83] X. Wang and W. Tian, “Green tea epigallocatechin gallate:
a natural inhibitor of fatty-acid synthase,” Biochemical and
Biophysical Research Communications, vol. 288, no. 5, pp. 1200–
1206, 2001.
[84] W. P. Xiao, R. Zhang, andY.H. Sun, “Enhancement of inhibitory
activity of green tea extract on fatty acid synthase by hydrogen
ion,”Chinese Journal of Biochemistry andMolecular Biology, vol.
22, pp. 234–238, 2006.
[85] Z. Rui, X. Wen-Ping, and T.Wei-Xi, “Inhibitory effects of green
tea extract on fatty acid synthase,” Journal of Yunnan University,
vol. 26, pp. 42–47, 2004.
[86] M.-H. Pan,C.-C. Lin, J.-K. Lin, andW.-J. Chen, “Tea polyphenol
(-)-epigallocatechin 3-gallate suppresses heregulin-𝛽1-induced
fatty acid synthase expression in human breast cancer cells
by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-
activated protein kinase cascade signaling,” Journal of Agricul-
tural and Food Chemistry, vol. 55, no. 13, pp. 5030–5037, 2007.
[87] T. Puig Miquel, J. Relat, P. F. Marrero, D. Haro, J. Brunet, and
R. Colomer, “Green tea catechin inhibits fatty acid synthase
without stimulating carnitine palmitoyltransferase-1 or induc-
ing weight loss in experimental animals,” Anticancer Research,
vol. 28, no. 6, pp. 3671–3676, 2008.
[88] M. J. Va´zquez, W. Leavens, R. Liu et al., “Discovery of
GSK837149A, an inhibitor of human fatty acid synthase target-
ing the 𝛽-ketoacyl reductase reaction,” FEBS Journal, vol. 275,
no. 7, pp. 1556–1567, 2008.
[89] T.M. Loftus,D. E. Jaworsky, C. L. Frehywot et al., “Reduced food
intake and body weight in mice treated with fatty acid synthase
inhibitors,” Science, vol. 288, no. 5475, pp. 2379–2381, 2000.
[90] J. N. Thupari, L. E. Landree, G. V. Ronnett, and F. P. Kuhajda,
“C75 increases peripheral energy utilization and fatty acid
16 Evidence-Based Complementary and Alternative Medicine
oxidation in diet-induced obesity,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 99, no.
14, pp. 9498–9502, 2002.
[91] Y. Zhang, “Induction of cancer cell apoptosis and growth
inhibition by icaritin is associated with its ability to suppress
fatty acid synthase activity,” China Academic Journal, 2009.
[92] G. K. Dae, H. Y. Ming, H. Oh, H. L. Dae, and S. L. Ho,
“Vasorelaxation by amentoflavone isolated from Selaginella
tamariscina,” Planta Medica, vol. 70, no. 8, pp. 718–722, 2004.
[93] Y.-M. Lin, H. Anderson, M. T. Flavin et al., “In vitro anti-
HIV activity of biflavonoids isolated fromRhus succedanea and
Garcinia multiflora,” Journal of Natural Products, vol. 60, no. 9,
pp. 884–888, 1997.
[94] A. Mora, M. Paya, J. L. Rios, and M. J. Alcaraz, “Structure-
activity relationships of polymethoxyflavones and other
flavonoids as inhibitors of non-enzymic lipid peroxidation,”
Biochemical Pharmacology, vol. 40, no. 4, pp. 793–797, 1990.
[95] W.-Y. Wu and Q.-G. Yu, “Grape seed extract in the fatty
acid synthase inhibitors, chemical composition and activity
determination,” Chinese Academic Journal, vol. 6, 2008.
[96] F. Yu, J. Gao, Y. Zeng, and C.-X. Liu, “Inhibition of Coix seed
extract on fatty acid synthase, a novel target for anticancer
activity,” Journal of Ethnopharmacology, vol. 119, no. 2, pp. 252–
258, 2008.
[97] W.-A. Ding, M. Du, and Y. Chen, “Study of coix seed chemical
composition and its mechanism of tumor and its prevention,”
Jilin Journal of Traditional Chinese Medicine, vol. 12, 2012.
[98] L. Y. Wang, F. Le, N. Wang et al., “Alteration of fatty acid
metabolism in the liver, adipose tissue, and testis of male mice
conceived through assisted reproductive technologies: fatty acid
metabolism in ART mice,” Lipids in Health and Disease, vol. 12,
article 5, 2013.
[99] Y. J. Choi, Y. Yoon, H. S. Choi et al., “Effects of medicinal herb
extracts and their components on steatogenic hepatotoxicity in
Sk-Hep1 cells,” Toxicology Research, vol. 27, pp. 211–216, 2011.
[100] B. Challier, J.-M. Perarnau, and J.-F. Viel, “Garlic, onion and
cereal fibre as protective factors for breast cancer: a French case-
control study,” European Journal of Epidemiology, vol. 14, no. 8,
pp. 737–747, 1998.
[101] A. Sengupta, S. Ghosh, and S. Bhattacharjee, “Allium vegetables
in cancer prevention: an overview,” Asian Pacific Journal of
Cancer Prevention, vol. 5, no. 3, pp. 237–245, 2004.
[102] Y. Wang, W. X. Tian, and X. F. Ma, “Inhibitory effects of
onion (Allium cepa L.) extract on proliferation of cancer cells
and adipocytes via inhibiting fatty acid synthase,” Asian Pacific
Journal of Cancer Prevention, vol. 13, pp. 5573–5579, 2012.
[103] C. Y. Ragasa, R. D. De Luna, W. C. Cruz Jr., and J. A.
Rideout, “Monoterpene lactones from the seeds of Nephelium
lappaceum,” Journal of Natural Products, vol. 68, no. 9, pp. 1394–
1396, 2005.
[104] Y.-X. Zhao, W.-J. Liang, H.-J. Fan et al., “Fatty acid synthase
inhibitors from the hulls of Nephelium lappaceum L,” Carbo-
hydrate Research, vol. 346, no. 11, pp. 1302–1306, 2011.
[105] W.-X. Tian, L.-C. Li, X.-D.Wu, and C.-C. Chen, “Weight reduc-
tion by Chinese medicinal herbs may be related to inhibition of
fatty acid synthase,” Life Sciences, vol. 74, no. 19, pp. 2389–2399,
2004.
[106] J.-B. Sun, X.-G. Lu, and J.-S. Tang, “The effect of compound
recipe TFR combined with exercise on the activity of FAS
to diet-induced hypercholesteremia rats,” Journal of Huaiyin
Teachers College, vol. 7, pp. 64–68, 2008.
[107] Y. Y. Zhang, F. Z. Zhang, L. Y. Sun, and X. Z. Wang, “Inhibition
to fatty acid synthase fromhuman breast cancer cell with extract
of Tuber Fleeceflower root in vitro,” Journal of Qiqihar Medical
College, vol. 25, pp. 1102–1104, 2004.
[108] W.-X. Tian, “Inhibition of fatty acid synthase by polyphenols,”
Current Medicinal Chemistry, vol. 13, no. 8, pp. 967–977, 2006.
[109] X. F. Ma, Y. Liu, and S. G. Zhang, “Relationship between
pharmic character of warm/cold traditional Chinese medicines
and their inhibition to fatty acid synthase,” Journal of Graduate
University of Chinese Academy of Sciences, vol. 29, pp. 699–706,
2012.
[110] H. Y. Song, L. Zhang, J. L. Pan, L. L. Yang, and G. Ji, “Bioactivity
of five components of Chinese herbal formula Jiangzhi granules
against hepatocellular steatosis,” Journal of Integrative Medicine,
vol. 11, pp. 262–268, 2013.
[111] H. S. Parekh, G. Liu, and M. Q. Wei, “A new dawn for the use
of traditional Chinese medicine in cancer therapy,” Molecular
Cancer, vol. 8, article 21, 2009.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
